Table 2. Analyses of the sensitivity of estimates to uncertainties in country data.
| Scenario | Maternal prevalence | CS case rate | CS case number: total | ABO number: total | ||||
|---|---|---|---|---|---|---|---|---|
| 2012 | 2016 | 2012 | 2016 | 2012 | 2016 | 2012 | 2016 | |
| Best estimate | 0.70% | 0.69% | 539 | 473 | 748,000 | 661,000 | 397,000 | 355,000 |
| Limit analysis to 100 countries with data for maternal prevalence and all 3 ANC coverage indicators | 0.76% | 0.66% | 558 | 427 | 503,000 | 383,000 | ||
| Move Group B & D countries (time-constant maternal prevalence on national data) into Group E (imputing regional, time-varying maternal prevalence) | 0.71% | 0.69% | 543 | 477 | 755,000 | 666,000 | 400,000 | 358,000 |
| Replace imputed ANC1 coverage by the worldwide lowest ANC1 coverage, at each of 2012 and 2016* | Unchanged | Unchanged | 541 | 475 | 752,000 | 664,000 | 398,000 | 357,000 |
| Replace imputed ANC1 coverage by the worldwide highest ANC1 coverage, at each of 2012 and 2016** | Unchanged | Unchanged | 538 | 473 | 748,000 | 661,000 | 396,000 | 355,000 |
| Replace imputed Screening coverage by the worldwide lowest screening coverage, at each of 2012 and 2016* | Unchanged | Unchanged | 569 | 508 | 791,000 | 709,000 | 418,000 | 379,000 |
| Replace imputed Screening coverage by the worldwide highest Screening coverage, at each of 2012 and 2016** | Unchanged | Unchanged | 508 | 445 | 706,000 | 621,000 | 376,000 | 336,000 |
| Replace imputed maternal syphilis treatment coverage by the worldwide lowest coverage, at each of 2012 and 2016* | Unchanged | Unchanged | 574 | 523 | 798,000 | 730,000 | 421,000 | 389,000 |
| Replace imputed maternal syphilis treatment coverage by the worldwide highest coverage, at each of 2012 and 2016** | Unchanged | Unchanged | 528 | 461 | 734,000 | 645,000 | 390,000 | 347,000 |
Notes to Table 2:
* Worldwide lowest coverage for ANC-1 attendance was 33.9% in 2012 and 40% in 2016; for screening coverage 0% and 6.3%, and for treatment coverage 9.2% and 26%.
** Worldwide highest coverage was 100% for ANC-1 attendance, screening and treatment, in both 2012 and 2016.